Targeted Oncology

Meet Dr. Oranus Mohammadi, MD, a board-certified oncologist at The Oncology Institute, who combines expertise with compassionate care to make a difference in the lives of his patients. With a dedication to providing the highest standard of treatment, Mohammadi is committed to guiding patients through their cancer journey with knowledge, empathy, and support. Learn more about her here! #OncologistSpotlight #DrOranusMohammadi #CancerCareExcellence #CompassionateOncology #OncologyInstitute

A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina Gasparetto, MD, on improving these processes. Duke Cancer Institute https://lnkd.in/gfSVSsht

The #FDA granted LBS-007 fast track designation for the treatment of patients with acute myeloid leukemia. #leusm https://lnkd.in/ga6BGqUC

In an interview, Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2+ biliary tract cancer treatment. MD Anderson Cancer Center https://lnkd.in/gSUxtn9Y

What does “extraordinary healer” mean to you? Think about a health care provider who consistently goes above and beyond to provide the best care. Does a certain oncology nurse come to mind? If so, nominate them for the 2025 Extraordinary Healer® award. This award and its accompanying event honor oncology nurses who dedicate their lives to service and make profound impacts on others. Submit your nomination today to show your appreciation for a family member, friend, health care provider or coworker. Nominations are open until December 11, 2024. https://ow.ly/Ns7g50UbW5Z #ExtraordinaryHealer #oncologynurse #CURE #cancercare

STC-15 was well tolerated with clinical activity seen across multiple tumor types, according to results from a phase 1 study. https://lnkd.in/e4taxqpj

An investigational breast cancer vaccine for triple-negative breast cancer showed encouraging results, with over 70% of patients exhibiting protocol-defined immune responses, according to findings from a phase 1 trial. #bcsm #TNBC #SITC24 https://lnkd.in/e8r68C-K

In an interview, Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care. #gyncsm https://lnkd.in/eWYsyfiU

The #FDA has received a BLA submission seeking the accelerated approval of RP1 plus nivolumab for the potential treatment of adult patients with advanced melanoma who have received prior treatment with a regimen that contains a PD-1 inhibitor. #melsm https://lnkd.in/eT83ZSSs

The #FDA has granted LBL-024 orphan drug designation for the treatment of neuroendocrine cancer. https://lnkd.in/gtcAkqDY